NYU School of Medicine Clinical Trails>>

Columbia University • Taub Institute

Clinical Trials

Safety and Efficacy of AC-3933 in Mild to Moderate AD

We are seeking men and women age 55 or older with mildto- moderate memory loss to participate in a Phase II study using the investigational drug, AC-3933. Each participant must have a family member or caregiver who can attend appointments during the research study. If interested, please contact Evelyn Dominguez at 212-305-2371.

Safety and Tolerability of AAB-001 in AD

We are seeking men and women age 50 to 85 with mildto- moderate AD to participate in a Phase IIA passive immunization study using the investigational drug, AAB-001. If interested, please contact Evelyn Dominguez at 212-305-2371.

Efficacy Study of MPC-7869 to Treat Patients with AD

We are seeking English and Spanish-speaking men and women, age 55 and older with mild-to-moderate AD to participate in a study to determine the effectiveness of MPC-7869 on cognitive and global function. MPC-7869 (Flurizan) is an anti-inflammatory drug that may also have an effect on beta-amyloid. If interested, please contact Evelyn Dominguez at 212-305-2371.

Valproate in Dementia (VALID) Study

Help us determine whether Valproate (a standard anticonvulsant medication) is effective in delaying or preventing the development of difficult behaviors (such as agitation or psychosis) in people with AD. This study will also determine whether Valproate slows the progression of AD. We are seeking English and Spanish-speaking men and women between 55 and 90 years of age to participate in the study. They must have a diagnosis of AD and have not experienced agitation or psychosis since the onset of the AD. If interested, please contact Ruth Tejeda at
212-305-766.

Antipsychotic Medication Treatment of Psychosis and Behavioral Dyscontrol in Alzheimer’s Disease Study

A research study funded by the National Institute of Aging will be treating people with AD who suffer from hallucinations, delusions, agitation, and/or aggression with risperidone, an FDA-approved antipsychotic medication. Each eligible participant must have a family member or caregiver who can assist with adherence to treatment and provide information during the research study. If interested, please contact Michelle Motta at 212-543-6132.

Mood and Memory Study

A study examining the benefit of treatment for depression in people (age 50+) with combined depression and mild memory problems is currently being conducted. In those depressed patients whose memory problem persists, further treatment with medication to improve memory will be offered. If interested, please contact Oliver Harper at 212-543-5067.

Neuroimaging Studies Alzheimer’s Disease Neuroimaging Study

We are seeking English and Spanish-speaking men and women age 55 to 90, who have normal memory, or mild memory problems, or early AD, to participate in a study to determine whether imaging of the brain with PET or MRI scans every 6 months can help predict and monitor the onset and progression of AD. In addition to the neuroimaging, the study will collect blood and, for some participants, cerebral spinal fluid to determine if biomarkers can predict and monitor the disease. No medication will be prescribed. To participate or get more information about the study, please contact Karina Stavitsky at 212-342-0522 or Rebecca Torgan at 212-305-1987.

Amyloid and Glucose Brain Imaging Research Study in People with Memory Problems

Help us understand the chemical pathways in the brain using a procedure called PET. Participants are reimbursed for procedures which include a PET scan and an MRI scan. These procedures are performed once at an initial visit and then again one year later. The study is for English-speaking men and women aged 50-89. If interested, please call Sara Rosenblum at 212-543-5956.

Other Studies

Genetic Linkage Study

We are seeking Caribbean Hispanic families from the Dominican Republic for a study to identify genes that may increase the risk for AD. If you have at least two living family members diagnosed with AD, please call Vincent Santana at 877- 636-5677 or Jennifer Williamson at 212-305-4655.

Additional Information Brain Donation Program “Give the Gift of Knowledge”

Brain donation allows valuable information to be obtained regarding normal aging and diseases that affect memory. This information may be useful towards the goal of developing more effective treatment strategies. If you or a family member wish to learn more about this program, please call Arlene Lawton, RN at 212-305-9086.

Lucy G. Moses Center for Memory and Behavioral Disorders

Changes in memory and thinking abilities can occur from a variety of conditions, not just Alzheimer’s disease. Taub Institute specialists offer a thorough multidisciplinary evaluation of memory and thinking difficulties at two locations: The Neurological Institute, 710 West 168th Street, New York, NY 10032; and Columbia Presbyterian Eastside, 16 East 60th Street, New York, NY 10022. For appointments, call: 212-305-6939.

NYU School of Medicine Clinical Trails>>

Previous | Next